Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma—a phase 3 randomised trial

• Chris Brown,
• Nick Pavlakis,
• Patrick M Forde,
• Julie Brahmer,
• Suresh Ramalingam,
• Valsamo Anagnostou,
• Brett Hughes,
• Martin Stockler,
• Anna K Nowak,
• Sonia Yip,
• Peey Sei Kok,
• Zhuoxin Sun,
• Alistair Cook,
• Willem Joost Lesterhuis,
• Ken O’Byrne,
• Kate Ford,
• Karen Fitzpatrick,
• Alison Bricker,
• Michelle M Cummins

Affiliations

Chris Brown

NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia

Nick Pavlakis

Genesis Care, Sydney, New South Wales, Australia

Patrick M Forde

Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA

Julie Brahmer

Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA

Suresh Ramalingam

Winship Cancer Institute, Emory University, Atlanta, Georgia, USA

Valsamo Anagnostou

Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA

Brett Hughes

Medical Oncology, Royal Brisbane and Women`s Hospital, Herston, Queensland, Australia

Martin Stockler

NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia

Anna K Nowak

National Centre for Asbestos Related Diseases (NCARD), Institute for Respiratory Health, Perth, Western Australia, Australia

Sonia Yip

NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia

Peey Sei Kok

NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia

Zhuoxin Sun

ECOG-ACRIN Biostatistics Center, Frontier Science Foundation, Boston, Massachusetts, USA

Alistair Cook

National Centre for Asbestos Related Diseases (NCARD), Institute for Respiratory Health, Perth, Western Australia, Australia

Willem Joost Lesterhuis

Telethon Kids Institute, Nedlands, Western Australia, Australia

Ken O’Byrne

Medical Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia

Kate Ford

NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia

Karen Fitzpatrick

PrECOG, Philadelphia, Pennsylvania, USA

Alison Bricker

PrECOG, Philadelphia, Pennsylvania, USA

Michelle M Cummins

NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia